

CADTH REIMBURSEMENT REVIEW

Stakeholder Feedback on Draft Recommendation

SELPERCATINIB (Retevmo)
Eli Lilly Canada Inc.

Indication: Retevmo is indicated as monotherapy for the treatment of: • RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.

June 16, 2022

Disclaimer: The views expressed in this submission are those of the submitting organization or individual. As such, they are independent of CADTH and do not necessarily represent or reflect the view of CADTH. No endorsement by CADTH is intended or should be inferred.

By filing with CADTH, the submitting organization or individual agrees to the full disclosure of the information. CADTH does not edit the content of the submissions.

CADTH does use reasonable care to prevent disclosure of personal information in posted material; however, it is ultimately the submitter's responsibility to ensure no identifying personal information or personal health information is included in the submission. The name of the submitting stakeholder group and all conflicts of interest information from individuals who contributed to the content are included in the posted submission.



CADTH Reimbursement Review Feedback on Draft Recommendation

| Stakeholder information | | | |
|--|--|-----------|-------------|
| CADTH project number | PC0274-000 | | |
| Brand name (generic) | Selpercatinib (Retevmo) | | |
| Indication(s) | Adult patients with RET fusion-positive | | |
| | differentiated thyroid carcinoma with advanced or | | |
| | metastatic disease (not amenable to surgery or radioactive | | |
| | iodine therapy) following prior treatment with sorafenib | | |
| | and/or lenvatinib | | |
| Organization | Ontario Health (CCO) Head, Neck and Thyroid Cancer Drug / | Adviso | ry |
| | Committee | | |
| Contact information ^a | Name: Dr. Michael Odell | | |
| Stakeholder agreement wi | th the draft recommendation | | |
| | | Yes | \boxtimes |
| 1. Does the stakeholder ag | ree with the committee's recommendation. | No | |
| | | | |
| Expert committee conside | eration of the stakeholder input | | |
| 2. Does the recommendation demonstrate that the committee has considered the | | Yes | \boxtimes |
| stakeholder input that your organization provided to CADTH? | | No | |
| | | | |
| Clarity of the draft recomm | nendation | | |
| 3 Are the reasons for the | recommendation clearly stated? | Yes | \boxtimes |
| o. Are the reasons for the | stated: | No | |
| | | | |
| 4. Have the implementation issues been clearly articulated and adequately | | Yes | \boxtimes |
| addressed in the recommendation? | | No | |
| F If amplicable and the main | | Voc | |
| 5. If applicable, are the reimbursement conditions clearly stated and the rationale for the conditions provided in the recommendation? | | Yes No | |
| ioi the conditions provided in the recommendation: | | | |
| | | | |

^a CADTH may contact this person if comments require clarification.

Appendix 2. Conflict of Interest Declarations for Clinician Groups

- To maintain the objectivity and credibility of the CADTH drug review programs, all participants in the drug review processes must disclose any real, potential, or perceived conflicts of interest.
- This conflict of interest declaration is required for participation. Declarations made do not negate or preclude the use of the feedback from patient groups and clinician groups.
- CADTH may contact your group with further questions, as needed.
- Please see the *Procedures for CADTH Drug Reimbursement Reviews* for further details.
- For conflict of interest declarations:
 - Please list any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.
 - Please note that declarations are required for each clinician that contributed to the input.
 - If your clinician group provided input at the outset of the review, only conflict of interest declarations that are new or require updating need to be reported in this form. For all others, please list the clinicians who provided input are unchanged
 - Please add more tables as needed (copy and paste).
 - All new and updated declarations must be included in a single document.

| A. Assistance with Providing the Feedback | | |
|---|-----|-------------|
| 1. Did you receive help from outside your clinician group to complete this submission? | No | |
| | Yes | \boxtimes |
| Ontario Health provided secretariat functions to the DAC. | | |
| 2. Did you receive help from outside your clinician group to collect or analyze any | No | \boxtimes |
| information used in this submission? | Yes | |
| | | |
| B. Previously Disclosed Conflict of Interest | | |
| 3. Were conflict of interest declarations provided in clinician group input that was | No | |
| submitted at the outset of the CADTH review and have those declarations remained unchanged? If no, please complete section C below. | | \boxtimes |
| If yes, please list the clinicians who contributed input and whose declarations have not changed: • Dr. Michael Odell • Dr. Stephanie Brule | | • |



CADTH Reimbursement Review

Feedback on Draft Recommendation

| Stakeholder information | |
|-------------------------|-----------------------|
| CADTH project number | PC0274 |
| Name of the drug and | PAG |
| Indication(s) | |
| Organization Providing | Selpercatinib for DTC |
| Feedback | |

| 1. Recommendate Please indicate if the recommendation. | ion revisions ne stakeholder requires the expert review committee to reconsider or clari | fy its |
|--|--|--------|
| Request for Reconsideration | Major revisions: A change in recommendation category or patient population is requested | |
| | Minor revisions: A change in reimbursement conditions is requested | |
| No Request for Reconsideration | Editorial revisions: Clarifications in recommendation text are requested | |
| | No requested revisions | Х |

| 2. Change in recommendation category or conditions |
|---|
| Complete this section if major or minor revisions are requested |
| None. |

| 3. Clarity of the recommendation Complete this section if editorial revisions are requested for the following elements |
|--|
| Complete this section in editorial revisions are requested for the following elements |
| a) Recommendation rationale |
| None. |
| |
| b) Reimbursement conditions and related reasons |
| None. |
| c) Implementation guidance |
| None. |
| |



CADTH Reimbursement Review Feedback on Draft Recommendation

| Stakeholder information | | |
|--|--|--|
| CADTH project number | PC0274-000 | |
| Brand name (generic) | RETEVMO™ (selpercatinib) | |
| Indication(s) | As monotherapy for the treatment of adult patients with rearra | anged |
| | during transfection (RET) fusion-positive differentiated thyroid | b |
| | carcinoma (DTC) with advanced or metastatic disease (not a | menable to |
| | surgery or radioactive iodine therapy) following prior treatmer | nt with |
| | sorafenib and/or lenvatinib | |
| Organization | Eli Lilly Canada Inc. | |
| Contact information ^a | | |
| | | |
| | | |
| Stakeholder agreement | with the draft recommendation | |
| | | Yes 🗵 |
| 1. Does the stakeholder agree with the committee's recommendation. | | No [|
| Eli Lilly Canada Inc. (Lilly) | agrees with the CADTH pCODR Expert Review Committee's (p | ERC) initia |
| recommendation that RETEVMO™ (selpercatinib) be reimbursed for the treatment of adult patients | | |
| recommendation that RE | TEVMO™ (selpercatinib) be reimbursed for the treatment of ac | dult patient |
| with RET fusion-positive | DTC with advanced or metastatic disease (not amenable to | surgery of |
| with RET fusion-positive radioactive iodine therapy | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly s | surgery of supports the |
| with RET fusion-positive radioactive iodine therapy conversion of the initial | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly strecommendation to a final recommendation to expedite access | surgery of supports the |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously tr | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly strecommendation to a final recommendation to expedite accesseated RET fusion-positive DTC. | surgery of supports the second |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously to Lilly is pleased with pERG | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly strecommendation to a final recommendation to expedite accesseated RET fusion-positive DTC. C's recognition of a poor prognosis and high unmet need for accessed to the commendation of a poor prognosis. | surgery of supports the second |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously to Lilly is pleased with pERG with RET fusion-positive | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly strecommendation to a final recommendation to expedite accesseated RET fusion-positive DTC. C's recognition of a poor prognosis and high unmet need for access DTC following progression on sorafenib and/or lenvatinib | surgery of supports the ss for adu dult patient o, and the |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously trulily is pleased with pERO with RET fusion-positive selpercatinib addresses a | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly serecommendation to a final recommendation to expedite accesseated RET fusion-positive DTC. C's recognition of a poor prognosis and high unmet need for access and the DTC following progression on sorafenib and/or lenvatinible an important therapeutic need as there are currently no funder | surgery of supports the ss for adu dult patient o, and the |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously to Lilly is pleased with pERG with RET fusion-positive | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly serecommendation to a final recommendation to expedite accesseated RET fusion-positive DTC. C's recognition of a poor prognosis and high unmet need for access and the DTC following progression on sorafenib and/or lenvatinible an important therapeutic need as there are currently no funder | surgery of supports the ss for adu dult patient o, and the |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously trulily is pleased with pERO with RET fusion-positive selpercatinib addresses a available in this patient policy. | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly serecommendation to a final recommendation to expedite accesseated RET fusion-positive DTC. C's recognition of a poor prognosis and high unmet need for access and the DTC following progression on sorafenib and/or lenvatinible an important therapeutic need as there are currently no funder | surgery of supports the ss for adu dult patient o, and the d therapie |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously trulily is pleased with pERO with RET fusion-positive selpercatinib addresses available in this patient positive selpercation and patient positive selpercation addresses available in this patient positive selpercation addresses available in this patient positive selpercation adverse effects. | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly strecommendation to a final recommendation to expedite accesseated RET fusion-positive DTC. C's recognition of a poor prognosis and high unmet need for access and the DTC following progression on sorafenib and/or lenvatinible an important therapeutic need as there are currently no funder appulation. Exercitinib potentially improves survival and is associated with fewer | surgery of supports the ss for adu dult patient o, and the d therapie |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously truling is pleased with pERO with RET fusion-positive selpercatinib addresses a available in this patient positive to the period of the p | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly serecommendation to a final recommendation to expedite accesseated RET fusion-positive DTC. C's recognition of a poor prognosis and high unmet need for accessed and the DTC following progression on sorafenib and/or lenvatinible an important therapeutic need as there are currently no funder upulation. Exercise the progression of the stakeholder input | surgery of supports the ss for adu dult patient of and the dight therapie |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously trulily is pleased with pERO with RET fusion-positive selpercatinib addresses available in this patient positive selpercation and the patient positive selpercation addresses available in this patient positive selpercation. Expert committee consideration and the provided adverse effects. | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly see recommendation to a final recommendation to expedite accesseated RET fusion-positive DTC. C's recognition of a poor prognosis and high unmet need for accessed and the DTC following progression on sorafenib and/or lenvatinible an important therapeutic need as there are currently no funder appulation. Percatinib potentially improves survival and is associated with fewer deration of the stakeholder input action demonstrate that the committee has considered the | surgery of supports the set for adult patient of and the different treatment of the set for the set fo |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously truling is pleased with pERO with RET fusion-positive selpercatinib addresses available in this patient positive available in this patient positive available in the patient positive selpercation addresses available in this patient positive selpercation. Expert committee considerate committee considerate adverse effects. Expert committee considerate adverse input that | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly serecommendation to a final recommendation to expedite accessed to the RET fusion-positive DTC. C's recognition of a poor prognosis and high unmet need for accessed to the DTC following progression on sorafenib and/or lenvatinible an important therapeutic need as there are currently no funder upulation. Exercition potentially improves survival and is associated with fewer action of the stakeholder input action demonstrate that the committee has considered the expour organization provided to CADTH? | surgery of supports the ss for adu dult patient of and the dight therapie |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously truling the self-self-self-self-self-self-self-self- | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly serecommendation to a final recommendation to expedite accesseated RET fusion-positive DTC. C's recognition of a poor prognosis and high unmet need for accessed to DTC following progression on sorafenib and/or lenvatinib an important therapeutic need as there are currently no funder upulation. Percatinib potentially improves survival and is associated with fewer deration of the stakeholder input ation demonstrate that the committee has considered the your organization provided to CADTH? Is considered the input provided to CADTH in its deliberation. | surgery of supports the set for adult patient of and the different treatment of the set for the set fo |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously truling is pleased with pERO with RET fusion-positive selpercatinib addresses available in this patient positive available in this patient positive adverse effects. Expert committee considerate adverse effects. Expert committee considerate adverse input that | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly serecommendation to a final recommendation to expedite accesseated RET fusion-positive DTC. C's recognition of a poor prognosis and high unmet need for accessed to DTC following progression on sorafenib and/or lenvatinib an important therapeutic need as there are currently no funder upulation. Percatinib potentially improves survival and is associated with fewer deration of the stakeholder input ation demonstrate that the committee has considered the your organization provided to CADTH? Is considered the input provided to CADTH in its deliberation. | surgery of supports the set for adult patients, and the distribution of the set for treatments. |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously truling the self-self-self-self-self-self-self-self- | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly serecommendation to a final recommendation to expedite accesseated RET fusion-positive DTC. C's recognition of a poor prognosis and high unmet need for accessed to DTC following progression on sorafenib and/or lenvatinib an important therapeutic need as there are currently no funder upulation. Percatinib potentially improves survival and is associated with fewer deration of the stakeholder input ation demonstrate that the committee has considered the your organization provided to CADTH? Is considered the input provided to CADTH in its deliberation. | surgery of supports the set for adult patients of and the different treatments of the set with the set of the |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously truling the self-self-self-self-self-self-self-self- | DTC with advanced or metastatic disease (not amenable to) following prior treatment with sorafenib and/or lenvatinib. Lilly strecommendation to a final recommendation to expedite accessed RET fusion-positive DTC. C's recognition of a poor prognosis and high unmet need for acceptance of the DTC following progression on sorafenib and/or lenvatinible an important therapeutic need as there are currently no funded expulation. Exercise the example of the stakeholder input action demonstrate that the committee has considered the expour organization provided to CADTH? Is considered the input provided to CADTH in its deliberation. Inmendation The recommendation clearly stated? | surgery of supports the set for adult patients, and the distribution of the set for treatments. |
| with RET fusion-positive radioactive iodine therapy conversion of the initial patients with previously truling the self-self-self-self-self-self-self-self- | DTC with advanced or metastatic disease (not amenable to following prior treatment with sorafenib and/or lenvatinib. Lilly strecommendation to a final recommendation to expedite accessed RET fusion-positive DTC. C's recognition of a poor prognosis and high unmet need for accessed and the progression on sorafenib and/or lenvatinib an important therapeutic need as there are currently no funded expulation. Exercition by potentially improves survival and is associated with fewer action of the stakeholder input action demonstrate that the committee has considered the your organization provided to CADTH? Is considered the input provided to CADTH in its deliberation. | surgery of supports the set for adult patients of and the different treatments of the set with the set of the |

| Lilly agrees that the implementation issues are clearly articulated and adequately addressed. | | | |
|---|--|-------------|--|
| 5. If applicable, are the reimbursement conditions clearly stated and the rationale | | \boxtimes | |
| for the conditions provided in the recommendation? | | | |
| Lilly agrees that the reimbursement conditions and associated rationales are clearly stated. | | | |

^a CADTH may contact this person if comments require clarification.